| Increase factor based on trials per year (2009 to 2003/4) | ||
---|---|---|---|
Trial characteristics | All trials | Non-inferiority | Equivalence |
Number of trials reported per year | 2.6 (2.1, 3.2) | 2.9 (2.3, 3.7) | 1.8 (1.2, 2.8) |
Inclusion of a placebo arm | 4.6 (2.2, 10.2) | 5.5 (2.4, 14.3) | 2.0 (0.3, 14.9) |
Comparison of different treatments | 2.0 (1.6, 2.6) | 2.4 (1.8, 3.1) | 1.1 (0.6, 2.0) |
Comparison of same treatments | 7.0 (4.3, 11.6) | 8.4 (4.7, 16.4) | 4.7 (2.1, 11.6) |
Two strategies | 6.1 (3.4, 11.5) | 7.1 (3.3, 16.9) | 4.9 1.9, 13.9) |
Two doses | 18.0 (5.5, 92.7) | 24.0 (6.0, 209.5) | 6.0 (0.5, 315.0) |
Two durations | 2.5 (0.5, 12.6) | 1.3 (0.1, 11.6) | 4.0 (0.2, 236.0) |
 | Absolute change in % (95% CI) of adherence (2009 to 2003/4) | ||
Criteria related to reporting quality | All trials | Non-inferiority | Equivalence |
Clearly identified as non-inferiority or equivalence trial in title or abstract | −15.6 (−20.8, -10.5) | na | na |
Trial described as double blind | −15.0 (20.8, 10.5) | −12.3 (−24.1, -0.6) | −13.0 (−33.6, 7.5) |
Justification of margin reported | 4.0 (−4.5, 12.5) | 2.1 (−7.7, 11.8) | 11.4 (−6.7, 29.5) |
Sample size calculation reported | 11.1 (3.5, 18.7) | 11.1 (2.5, 19.7) | 9.6 (−6.6, 25.9) |
All elements for recalculation of sample size reported | 5.6 (−4.5, 15.8) | 8.0 (−3.7, 19.6) | −4.6 (−25.5, 16.3) |
Criteria related to methodological quality | Â | Â | |
Non-inferiority or equivalence margin defined | −2.0 (−6.3, 2.3) | −0.1 (−4.5, 4.2) | −9.9 (−22.1, 2.2) |
Sample size calculation taking into account the margin | 6.4 (−2.6, 15.3) | 11.6 (1.4, 21.8) | −11.8 (−30.8, 7.2) |
Results reported using confidence interval | 0.7 (−6.7, 6.2) | 3.1 (−5.7, 12.0) | −5.8 (−20.2, 8.6) |
Both per-protocol and ITT/modified ITT-analysis reported | −1.0 (−11.1, 9.2) | 0.4 (−11.4, 12.1) | −8.2 (−28.1, 11.7) |
All 4 methodological quality criteria fulfilled | 14.1 (5.1, 23.0) | 17.0 (6.6, 27.5) | 1.9 (−15.0, 18.8) |